CJC-1295 (with DAC)
CJC-1295 + DAC (Drug Affinity Complex) is a synthetic GHRH (Growth Hormone Releasing Hormone) analog with trans-3,6-dimethyl-octanoyl modification, extending half-life to 6–8 days vs. natural GHRH’s 7 minutes. Binds albumin for continuous pituitary stimulation, yielding 3–10x baseline GH/IGF-1 levels. Researched for GH deficiency, body comp, anti-aging, and recovery—sustained release differentiates from no-DAC pulses.
DAC Advantage: Weekly dosing; steady IGF-1 curve.
Mechanism
- GHRH Receptor: ↑cAMP → GH synthesis/release.
- DAC Extension: Fatty acid → albumin binding → slow dissociation.
- Downstream: IGF-1 ↑ → anabolism, lipolysis.
PK Profile: Peak GH 1–2 days post-dose; trough elevated.
Research Evidence
| Effect | Studies/Outcomes |
|---|---|
| GH/IGF-1 | 2–10x GH AUC, IGF-1 +200–1000% (Phase I, Endocrinol 2006). |
| Body Comp | Fat -10–15%, lean +5–8% (12w, healthy men). |
| Lipids/Bone | LDL ↓20%, BMD ↑ (long-term). |
| Sleep/Recovery | Deep sleep ↑ via GH. |
Protocols (Research Contexts)
| Goal | Dose (mcg/week) | Frequency | Cycle |
|---|---|---|---|
| Bulking/GH | 1000–2000 | 1–2x/week | 12–16w on/4w off |
| Fat Loss | 500–1000 | 2x/week | 8–12 weeks |
| Anti-Aging | 250–500 | Weekly | Long-term |
| Recovery | 500–1000 | 1x/week | PRN |
- Recon: 2ml bac water (5mg vial = 250mcg/0.1ml).
- Timing: Any; consistent day.
- Stack: Ipamorelin (pulse on DAC base), MK-677.
Benefits
- Sustained Anabolism: Protein synthesis ↑.
- Fat Reduction: Visceral target.
- Wellness: Sleep, skin, joints.
- Convenience: Weekly vs. daily.
Side Effects & Safety
| Common | Serious (Manageable) | Mitigation |
|---|---|---|
| Water retention, numbness | Pituitary desensitization | Lower dose, cycle |
| Fatigue, hunger | IGF-1 cancer promotion? | Monitor tumors |
- Desensitization: CJC-1295 + DAC, Rare <2w continuous; pulses prevent.
- Labs: IGF-1 q4w (<350ng/ml target).
Comparisons
| GHRH Variant | Half-Life | Dosing | Pulsatile? |
|---|---|---|---|
| CJC w/DAC | 6–8d | Weekly | No (steady) |
| CJC no-DAC | 30min | 2–3x/day | Yes |
| Sermorelin | 10–20min | Daily | Yes |
| Tesamorelin | 30min | Daily | HIV lipodystrophy |
Status
- Research Chemical: CJC-1295 + DAC, Patented; WADA-monitored.
- Vs. No-DAC: Steady vs. pulse—DAC for compliance.
Disclaimer: Research-only; bloodwork essential.
| QUANTITY | 2mg, 5mg |
|---|
Reviews
There are no reviews yet.
Related products
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Endocrine Pathway Research Peptides (GHRPs, GHRHs, GnRHs)
Be the first to review “CJC-1295 (with DAC)”